Life Cycle Investment Partners Ltd Invests $30.71 Million in Elevance Health, Inc. $ELV

Life Cycle Investment Partners Ltd acquired a new position in shares of Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 87,604 shares of the company’s stock, valued at approximately $30,710,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ELV. Physician Wealth Advisors Inc. grew its position in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares in the last quarter. Activest Wealth Management grew its position in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares in the last quarter. Rossby Financial LCC grew its position in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. ORG Partners LLC grew its position in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Elevance Health during the fourth quarter worth about $38,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Price Performance

ELV stock opened at $394.41 on Friday. The business has a 50 day moving average price of $333.81 and a 200 day moving average price of $336.25. The stock has a market cap of $85.65 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 2.23 and a beta of 0.66. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $408.00. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the business earned $11.97 earnings per share. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts anticipate that Elevance Health, Inc. will post 26.91 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.

Analyst Ratings Changes

A number of equities analysts have recently commented on ELV shares. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $405.00 to $435.00 in a research report on Wednesday, April 29th. Wells Fargo & Company decreased their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. UBS Group boosted their target price on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Finally, Mizuho boosted their target price on Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $399.32.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.